埃萬妥單抗聯(lián)合治療方案為不同EGFR突變晚期NSCLC人群提供精準(zhǔn)治療選擇。

*以下內(nèi)容僅供醫(yī)療衛(wèi)生專業(yè)人士瀏覽。

參考文獻(xiàn)：

[1] 中華醫(yī)學(xué)會腫瘤學(xué)分會. 中華醫(yī)學(xué)會肺癌臨床診療指南（2025版）[J]. 中華腫瘤雜志, 2025, 47(9): 769-810.

[2] Boustany Y, et al. Prevalence and Patterns of EGFR Mutations in Non-small Cell Lung Cancer in the Middle East and North Africa. Cancer Control. 2022;29: 1-9.

[3] Zhou C, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051.

[4] Zhou C. et al. Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysis. 2023 ESMO Asia.513MO.

[5]Cho BC, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024 Oct 24;391(16):1486-1498.

[6]Yang JC, et al. MARIPOSA Investigators. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025 Sep 7.

[7]Lu S, et al. Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment Among Asian Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): MARIPOSA Subgroup Analysis. 2023 ESMO Aisa. LBA10.

審批編碼：CP-558517

批準(zhǔn)分發(fā)日期：12/16/2025

有效期：12/16/2026

*“醫(yī)學(xué)界”力求所發(fā)表內(nèi)容專業(yè)、可靠，但不對內(nèi)容的準(zhǔn)確性做出承諾；請相關(guān)各方在采用或以此作為決策依據(jù)時另行核查。